Loading…

Cuorips Inc.4894.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Biotechnology
Momentum neutral 47
Mkt cap
$309M
US dollars, full cap
Free float
70%
of shares outstanding
$/day
$7.73M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-63.8 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
92 days
18 Feb 2027
Close · JPY¥5,630
1D+0.5%
1W-17.4%
1M-8.6%
3M+4.3%
6M-10.3%
YTD-6.6%
1Y-15.8%
ATR %7.2%
52w lowhigh54.6% off high

What Cuorips does

Employees: 51

Cuorips at a glance

Size Cuorips (4894.T) is a Japan Health Care company (Biotechnology) with a market value of $309M, the 1338th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥5,630 on 18 Nov 2026.

Performance Over six months the shares fell 10.3%, against -31.0% for the median peer and -1.4% for the Japan market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue fell 80.0% over the last twelve months (peer median +7.3%); the operating margin is -1,764.6% (peer median -115.0%).

Valuation It trades at 602.9× enterprise value to sales against a peer median of 5.3× (3rd most expensive of 15).

Capital Return on invested capital runs 63.8 points below its cost of capital (5.0% WACC).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 20264894.T 101Peer median 69
Six months, rebased to 100: Cuorips against the median of its 20 peers (local-currency closes).

Cuorips financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥72.0M¥212M¥175M¥23.1M¥38.3M
Revenue growth—+21%+658%-40%—
Gross profit-¥64.6M¥45.9M¥91.6M-¥60.5M-¥57.6M
EBITDA-¥1.16B-¥997M-¥514M-¥518M-¥372M
Net income-¥1.07B-¥1.02B-¥644M-¥632M-¥452M
Free cash flown/a-¥1.10B-¥893M-¥475M-¥407M
Capital expendituren/a¥49.8M¥89.8M¥35.9M¥10.6M
Total debt¥1.00B¥0¥0¥0¥0

Quarterly statements and history in the cockpit →

Cuorips competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-25%0%+25%NAUTXFOR1873PROKGLSIGALT76306945CCCC21053880LRMR358570LYEL086900CRMDCTNM4760604894.T6-month return →1-month return →
Up and to the right = strong over both horizons. Cuorips is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×5,000×10,000×15,000×XFOR1873PROK7630358570LYEL4760604894.TRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cuorips is the large dot.

Cuorips competitors and peer comparison

How Cuorips compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cuorips against its 20 peers (data as of 18 Nov 2026)
Measure4894.TPeer medianRank in peer set
1-month return-8.6%-4.7%9th lowest of 20
6-month return-10.3%-31.0%4th highest of 20
Distance from 52-week high-54.6%-52.1%10th lowest of 20
Revenue growth (TTM)-80.0%+7.3%lowest of 13
Operating margin-1,764.6%-115.0%4th lowest of 15
EV / Sales602.9×5.3×3rd most expensive of 15
ROIC minus cost of capital-63.8 pp-22.1 pp7th lowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Cuorips 4894.TJapan$309M-10%-80%-1,765%602.9×n/an/a
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%11.4×n/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%1.0×2.6%+19.1%
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a
Galectin Therapeutics GALTUnited States$301M+35%n/an/an/an/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a

Questions

Which companies are Cuorips's closest peers?
The cockpit's peer set: Nautilus Biotechnolgy (NAUT), X4 Pharmaceuticals (XFOR), Viva Biotech (1873.HK), ProKidney (PROK), Greenwich LifeSciences (GLSI), Galectin Therapeutics (GALT), IMPACT Therapeutics (7630.HK), AP Biosciences (6945.TWO).
Is Cuorips expensive compared with its peers?
On ev / sales it trades at 602.9× against a peer median of 5.3×, 3rd most expensive of 15 in its peer set.
How has Cuorips stock performed?
Over six months to 18 Nov 2026 the shares returned -10.3% against -31.0% for the median peer; over one year -15.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.